Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)
LISATA THERAPEUTICS, INC.
Stage IV Melanoma
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.
The George Institute
Metastatic colorectal cancer
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion
The George Institute
intermediate-stage hepatocellular carcinoma
1 trial -
Azacitidine Combined With Venetoclax and ATRA group
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Azathioprine
The First People's Hospital of Lianyungang
Myasthenia Gravis
1 trial -
Azeliragon
vTv Therapeutics
Alzheimer's Disease
1 trial -
Azeliragon 5mg
vTv Therapeutics
Alzheimer's Disease
1 trial -
Azithromycin plus hydroxychloroquine
Iterum Therapeutics plc
Respiratory Tract Infection Viral
1 trial -
B007
BRIGHT MINDS BIOSCIENCES INC.
Generalized Myasthenia Gravis
1 trial -
BAT5906 injection
Bio-Thera Solutions
Diabetic Macular Edema (DME)
1 trial -
BAY 3427080, BAY 3427080 60 mg capsules placebo
Bayer AG
Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer
1 trial -
BAY 94-8862, Finerenone, Placebo coated tablet 002 to BAY 948862 coated tablet
The George Institute
Chronic kidney disease
1 trial -
BCG (Tokyo 172) vaccine
United Therapeutics Europe Ltd
Tuberculosis Infection
1 trial -
BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin
The George Institute
Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.
1 trial -
BEP(500)
United Therapeutics Europe Ltd
Stage I Testicular Non-Seminomatous Germ Cell Tumor
1 trial -
BETAMETHASONE, Placebo of fludrocortisone, HYDROCORTISONE HEMISUCCINATE, Placebo of hydrocortisone, FLUDROCORTISONE
Pari Pharma GmbH
Patients admitted to the ICU proven or suspected infection as the main diagnosis.
1 trial -
BGJ398
BridgeBio Oncology Therapeutics
Advanced Cholangiocarcinoma
1 trial -
BIIB059
Biogen
1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus
1 trial -
BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059
Biogen
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
1 trial -
BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient
Biogen
systemic lupus erythematosus
1 trial -
BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient
Biogen
systemic lupus erythematosus
1 trial -
BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.
Biogen
Systemic lupus erythematosus
1 trial -
BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]
Biogen
Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources